These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 32297948)

  • 1. Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors.
    Nomura M; Nagatomo R; Doi K; Shimizu J; Baba K; Saito T; Matsumoto S; Inoue K; Muto M
    JAMA Netw Open; 2020 Apr; 3(4):e202895. PubMed ID: 32297948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Chen SJ; Chen CC; Liao HY; Lin YT; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
    Neurology; 2022 Feb; 98(8):e848-e858. PubMed ID: 34996879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors.
    Lei M; Michael A; Patel S; Wang D
    J Oncol Pharm Pract; 2019 Sep; 25(6):1402-1411. PubMed ID: 30782080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.
    Massarelli E; William W; Johnson F; Kies M; Ferrarotto R; Guo M; Feng L; Lee JJ; Tran H; Kim YU; Haymaker C; Bernatchez C; Curran M; Zecchini Barrese T; Rodriguez Canales J; Wistuba I; Li L; Wang J; van der Burg SH; Melief CJ; Glisson B
    JAMA Oncol; 2019 Jan; 5(1):67-73. PubMed ID: 30267032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
    JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
    Inoue Y; Yoshimura K; Nishimoto K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Sugimura H; Suda T
    JAMA Netw Open; 2020 Sep; 3(9):e2011818. PubMed ID: 32955570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and comparison of short chain fatty acids composition in gut diseases.
    Niccolai E; Baldi S; Ricci F; Russo E; Nannini G; Menicatti M; Poli G; Taddei A; Bartolucci G; Calabrò AS; Stingo FC; Amedei A
    World J Gastroenterol; 2019 Sep; 25(36):5543-5558. PubMed ID: 31576099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
    Yang X; Ai P; He X; Mo C; Zhang Y; Xu S; Lai Y; Qian Y; Xiao Q
    Mov Disord; 2022 Aug; 37(8):1634-1643. PubMed ID: 35607987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
    Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
    J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
    Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
    JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
    Shazib MA; Woo SB; Sroussi H; Carvo I; Treister N; Farag A; Schoenfeld J; Haddad R; LeBoeuf N; Villa A
    Oral Dis; 2020 Mar; 26(2):325-333. PubMed ID: 31642136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS).
    Ratajczak W; Mizerski A; Rył A; Słojewski M; Sipak O; Piasecka M; Laszczyńska M
    Aging (Albany NY); 2021 Apr; 13(8):10934-10954. PubMed ID: 33847600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and Optimization of Sample Handling Methods for Quantification of Short-Chain Fatty Acids in Human Fecal Samples by GC-MS.
    Hsu YL; Chen CC; Lin YT; Wu WK; Chang LC; Lai CH; Wu MS; Kuo CH
    J Proteome Res; 2019 May; 18(5):1948-1957. PubMed ID: 30895795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data-Driven Analysis on a Nationwide Cohort.
    Yang S; Yu KH; Palmer N; Fox K; Kou SC; Kohane IS
    Clin Pharmacol Ther; 2020 Feb; 107(2):388-396. PubMed ID: 31356677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
    Berner F; Bomze D; Diem S; Ali OH; Fässler M; Ring S; Niederer R; Ackermann CJ; Baumgaertner P; Pikor N; Cruz CG; van de Veen W; Akdis M; Nikolaev S; Läubli H; Zippelius A; Hartmann F; Cheng HW; Hönger G; Recher M; Goldman J; Cozzio A; Früh M; Neefjes J; Driessen C; Ludewig B; Hegazy AN; Jochum W; Speiser DE; Flatz L
    JAMA Oncol; 2019 Jul; 5(7):1043-1047. PubMed ID: 31021392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.